Coastline Trust Co Lowers Stake in DaVita Inc. (NYSE:DVA)

Coastline Trust Co lowered its stake in shares of DaVita Inc. (NYSE:DVAFree Report) by 52.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,080 shares of the company’s stock after selling 2,300 shares during the period. Coastline Trust Co’s holdings in DaVita were worth $218,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in DVA. Norges Bank acquired a new position in shares of DaVita during the fourth quarter worth $116,373,000. Deutsche Bank AG increased its position in shares of DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after acquiring an additional 885,195 shares during the period. Amundi increased its position in shares of DaVita by 226.3% in the 4th quarter. Amundi now owns 659,372 shares of the company’s stock valued at $52,592,000 after acquiring an additional 457,285 shares during the period. Morgan Stanley increased its position in shares of DaVita by 37.9% in the 4th quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock valued at $92,042,000 after acquiring an additional 339,051 shares during the period. Finally, Point72 Asset Management L.P. increased its position in shares of DaVita by 912.4% in the 4th quarter. Point72 Asset Management L.P. now owns 338,139 shares of the company’s stock valued at $25,249,000 after acquiring an additional 304,739 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on DVA. Barclays began coverage on DaVita in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 target price on the stock. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Truist Financial increased their price target on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Finally, UBS Group increased their price target on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $118.50.

View Our Latest Stock Analysis on DVA

DaVita Trading Up 0.2 %

DVA stock opened at $135.29 on Thursday. The company’s 50-day simple moving average is $125.63 and its 200-day simple moving average is $106.37. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $141.54. The firm has a market cap of $11.86 billion, a P/E ratio of 18.28, a PEG ratio of 1.20 and a beta of 1.04.

DaVita (NYSE:DVAGet Free Report) last posted its earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.01 billion. During the same period in the prior year, the company posted $1.11 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, equities analysts forecast that DaVita Inc. will post 9.23 EPS for the current fiscal year.

Insider Activity at DaVita

In related news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Kathleen Alyce Waters sold 11,285 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the transaction, the insider now directly owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider James O. Hearty sold 26,164 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is owned by corporate insiders.

DaVita Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Articles

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVAFree Report).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.